DiaMedica Therapeutics Inc (NASDAQ:DMAC) was the recipient of a large drop in short interest during the month of August. As of August 15th, there was short interest totalling 10,800 shares, a drop of 68.4% from the July 15th total of 34,200 shares. Based on an average trading volume of 109,700 shares, the short-interest ratio is presently 0.1 days. Currently, 0.1% of the company’s shares are short sold.
In other DiaMedica Therapeutics news, Director Richard D. Pilnik purchased 19,000 shares of the firm’s stock in a transaction that occurred on Friday, May 31st. The stock was purchased at an average cost of $2.80 per share, with a total value of $53,200.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have purchased a total of 30,840 shares of company stock valued at $83,240 over the last three months. 12.80% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Worth Venture Partners LLC increased its holdings in DiaMedica Therapeutics by 10.6% during the 2nd quarter. Worth Venture Partners LLC now owns 132,514 shares of the company’s stock worth $657,000 after purchasing an additional 12,651 shares during the period. BlackRock Inc. increased its holdings in DiaMedica Therapeutics by 159.7% during the 2nd quarter. BlackRock Inc. now owns 27,075 shares of the company’s stock worth $134,000 after purchasing an additional 16,651 shares during the period. Vanguard Group Inc. purchased a new position in DiaMedica Therapeutics during the 2nd quarter worth $170,000. Eidelman Virant Capital purchased a new position in DiaMedica Therapeutics during the 2nd quarter worth $173,000. Finally, Granite Point Capital Management L.P. purchased a new position in DiaMedica Therapeutics during the 2nd quarter worth $1,141,000. Institutional investors own 8.73% of the company’s stock.
DMAC traded down $0.01 during trading on Wednesday, hitting $2.50. 216 shares of the stock were exchanged, compared to its average volume of 55,483. The firm has a 50 day simple moving average of $3.37 and a 200 day simple moving average of $3.51. DiaMedica Therapeutics has a 1 year low of $2.15 and a 1 year high of $5.93. The company has a current ratio of 12.96, a quick ratio of 12.96 and a debt-to-equity ratio of 0.01.
DiaMedica Therapeutics (NASDAQ:DMAC) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.07. Analysts forecast that DiaMedica Therapeutics will post -0.91 earnings per share for the current year.
DiaMedica Therapeutics Company Profile
DiaMedica Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications.
Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.